{"id":798916,"date":"2025-01-08T08:33:11","date_gmt":"2025-01-08T13:33:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/"},"modified":"2025-01-08T08:33:11","modified_gmt":"2025-01-08T13:33:11","slug":"genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/","title":{"rendered":"GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients<\/b><\/p>\n<p class=\"bwalignc\"><i>Contributed nearly one quarter of all submissions to GeneMatcher and collaborated on more than 85 peer reviewed publications in 2024<\/i><\/p>\n<p>STAMFORD, Conn.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nGeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, continues its investment in advancing scientific discovery through understanding gene-disease relationships, contributing to more than 85 peer-reviewed publications in 2024. These contributions, added to GeneDx\u2019s years of dedicated research efforts, influenced the broadening of phenotypes, the discovery of new disease mechanisms and new modes of inheritance, and ultimately impacted results of 12% of all patients who have received exome or genome sequencing from GeneDx.<\/p>\n<p>\nIn 2024, GeneDx also contributed nearly one quarter of all submissions to GeneMatcher, a platform that facilitates disease-gene discovery by sharing genetic findings among patients, clinicians, and researchers. For each \u201ccandidate gene\u201d\u2014a gene that is highly suspected (but not yet proven) to be linked to a specific disease\u2014identified by GeneDx, the lab submits the finding to GeneMatcher, which then connects researchers and clinicians around the world so they can work together to better understand genetic contributions to rare disease. To date, this research has impacted &gt;22,000 patients tested at GeneDx and, in the future, will influence the results of many additional patients seeking diagnoses or answers.<\/p>\n<p>\n\u201cThe combination of our high-quality genomic testing and our dedicated involvement in research keeps GeneDx at the forefront of genomics and uniquely positions us to influence the future of healthcare,\u201d said Paul Kruszka, MD, FACMG, Chief Medical Officer at GeneDx. \u201cWe\u2019re committed to improving the lives of patients and their families by delivering definitive diagnoses, and that ultimately begins with a deep understanding of gene-disease relationships. We\u2019re honored to contribute our knowledge to the broader scientific community to ultimately help more patients.\u201d<\/p>\n<p><b>By the numbers<\/b><\/p>\n<p>\nGeneDx is a leader in scientific inquiry, striving to find answers for more patients. Through ongoing research efforts in 2024, GeneDx:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nContributed to 86 publications in peer reviewed journals, bringing the total to over 1,121 publications to date and demonstrating the company\u2019s leadership in the commercial laboratory space<\/p>\n<\/li>\n<li>\nCollaborated on 26 publications that expanded current knowledge of known disease-gene associations, including broadening phenotypes, new disease mechanisms, and new modes of inheritance<\/p>\n<\/li>\n<li>\nCollaborated on 35 publications that reported new disease-gene relationships<\/p>\n<\/li>\n<li>\nIncreased its cumulative GeneMatcher submissions to more than 21,315\u2014accounting for 22.2% of all such submissions and making GeneDx the largest contributor of the 16,812 laboratories, researchers, and clinicians taking part in the initiative<\/p>\n<\/li>\n<\/ul>\n<p>\nRecognizing that GeneDx ordering clinicians have a vested interest in finding definitive answers for their patients, GeneDx proactively invites them to take part in research around their patients\u2019 candidate gene results. In 2024, almost 150 GeneDx ordering clinicians were included as co-authors on the company\u2019s GeneMatcher publications, bringing the all-time total to 638 unique ordering clinician co-authors.<\/p>\n<p>\nThese endeavors underscore the company\u2019s commitment to improving healthcare for rare disease patients through genomic answers, its dedication to involving ordering clinicians in research efforts that benefit their patients, and its impact on the fundamental understanding of genetics\u2014powering future treatment advancements and innovation.<\/p>\n<p><b><span class=\"bwuline\">About GeneDx<\/span><\/b>:<br \/>\n<br \/>GeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation services, fueled by the world\u2019s largest, rare disease data sets. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.genedx.com%2F&amp;esheet=54174083&amp;newsitemid=20250107093718&amp;lan=en-US&amp;anchor=www.genedx.com&amp;index=1&amp;md5=7218c328ab38e5e06744e229ecd68758\">www.genedx.com<\/a> and connect with us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fgenedx&amp;esheet=54174083&amp;newsitemid=20250107093718&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=809cbb28687fee0109e8ac335b8580cc\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FGeneDxLab%2F&amp;esheet=54174083&amp;newsitemid=20250107093718&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=470f66771ca022d3956509a508e63944\">Facebook<\/a>, and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fgenedxlab%2F%3Fhl%3Den&amp;esheet=54174083&amp;newsitemid=20250107093718&amp;lan=en-US&amp;anchor=Instagram&amp;index=4&amp;md5=45feb16f0a56f65ad64845d400e22158\">Instagram<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250107093718r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250107093718\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250107093718\/en\/<\/a><\/span><\/p>\n<p>\nMedia<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Press@GeneDx.com\">Press@GeneDx.com<\/a><\/p>\n<p>\nInvestors<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Investors@genedx.com\">Investors@genedx.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Connecticut United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Medical Devices Hospitals Genetics Clinical Trials Biotechnology Managed Care Health Pharmaceutical General Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250107093718\/en\/2177257\/3\/General_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients Contributed nearly one quarter of all submissions to GeneMatcher and collaborated on more than 85 peer reviewed publications in 2024 STAMFORD, Conn.&#8211;(BUSINESS WIRE)&#8211; GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, continues its investment in advancing scientific discovery through understanding gene-disease relationships, contributing to more than 85 peer-reviewed publications in 2024. These contributions, added to GeneDx\u2019s years of dedicated research efforts, influenced the broadening of phenotypes, the discovery of new disease mechanisms and new modes of inheritance, and ultimately impacted results of 12% of all patients who have received exome or genome sequencing from GeneDx. In 2024, GeneDx also &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-798916","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients Contributed nearly one quarter of all submissions to GeneMatcher and collaborated on more than 85 peer reviewed publications in 2024 STAMFORD, Conn.&#8211;(BUSINESS WIRE)&#8211; GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, continues its investment in advancing scientific discovery through understanding gene-disease relationships, contributing to more than 85 peer-reviewed publications in 2024. These contributions, added to GeneDx\u2019s years of dedicated research efforts, influenced the broadening of phenotypes, the discovery of new disease mechanisms and new modes of inheritance, and ultimately impacted results of 12% of all patients who have received exome or genome sequencing from GeneDx. In 2024, GeneDx also &hellip; Continue reading &quot;GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-08T13:33:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250107093718r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients\",\"datePublished\":\"2025-01-08T13:33:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\\\/\"},\"wordCount\":665,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250107093718r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\\\/\",\"name\":\"GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250107093718r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-01-08T13:33:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250107093718r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250107093718r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/","og_locale":"en_US","og_type":"article","og_title":"GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients - Market Newsdesk","og_description":"GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients Contributed nearly one quarter of all submissions to GeneMatcher and collaborated on more than 85 peer reviewed publications in 2024 STAMFORD, Conn.&#8211;(BUSINESS WIRE)&#8211; GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, continues its investment in advancing scientific discovery through understanding gene-disease relationships, contributing to more than 85 peer-reviewed publications in 2024. These contributions, added to GeneDx\u2019s years of dedicated research efforts, influenced the broadening of phenotypes, the discovery of new disease mechanisms and new modes of inheritance, and ultimately impacted results of 12% of all patients who have received exome or genome sequencing from GeneDx. In 2024, GeneDx also &hellip; Continue reading \"GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-08T13:33:11+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250107093718r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients","datePublished":"2025-01-08T13:33:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/"},"wordCount":665,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250107093718r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/","name":"GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250107093718r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-01-08T13:33:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250107093718r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250107093718r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-continues-its-leadership-in-genomics-research-refining-gene-disease-relationships-and-impacting-results-of-22000-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of &gt;22,000 Patients"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=798916"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798916\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=798916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=798916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=798916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}